慢性腰痛の世界市場の評価：薬剤クラス・投与経路・エンドユーザー・地域別の機会および予測 (2017～2031年)

世界の慢性腰痛の市場規模は、2024年から2031年の予測期間中にCAGR 6.22％を記録し、2023年の80億2,000万米ドルから、2031年には129億9,000万米ドルの規模に成長すると予測されています。

慢性腰痛の市場は、慢性腰痛の有病率の増加、高齢化人口の増加、座りがちなライフスタイル、肥満の有病率の増加、疼痛管理ソリューションの進歩、健康意識の高まりなどの促進要因の影響を受けて拡大すると予測されています。企業産業の成長に伴い、人々は長時間座ったままで仕事をすることを余儀なくされており、これが罹患者数の多い主な原因となっています。

また、老齢人口が増加し、身体の消耗や損傷のリスクが高まっていることも、慢性疼痛が増加している主な要因です。慢性疼痛管理は、主に非ステロイド性抗炎症薬、鎮痛薬、オピオイドなどの薬剤クラス別に、経口または局所投与によって行われています。

腰痛の有病率の増加

慢性腰痛の市場は、脊椎疾患や腰痛症例の有病率の増加により拡大が見込まれています。高齢者は、加齢に伴う脊椎の自然な磨耗や損傷により、脊椎障害のリスクが高くなります。その結果、脊椎障害の症例数が大幅に増加すると予測されています。さらに、肥満、長時間座りっぱなしの社会人、栄養不良、運動不足、腰痛を引き起こす事故の多発といった要因も、腰痛の増加に寄与すると予想されています。脊椎や腰の組織を損傷する遺伝性疾患、炎症、感染症も腰痛の有病率の増加に寄与しています。

疼痛管理のための新薬開発への注目の高まり

疼痛管理のための新規薬剤の開発は、医療分野でますます注目されています。研究者や製薬会社は、疼痛緩和のための革新的な薬物標的やドラッグデリバリーシステムの特定と開発にますます重点を置くようになっています。これには、痛みの伝達や調節に関与する特定の受容体、イオンチャネル、シグナル伝達経路を標的とすることも含まれます。さらに、鎮痛薬の有効性を高め、副作用を抑えるために、ナノテクノロジーに基づくドラッグデリバリーシステムがメーカーにより研究されています。腰痛を管理するためのより適切で安全な選択肢の追求が、市場の範囲をさらに拡大しています。

非ステロイド性抗炎症薬 (NSAIDs) 部門の優位性

NSAIDs部門は、その有効性の広さと人気の高さから市場を独占すると予想されています。NSAIDsは、腰痛を含む筋骨格系の痛みに等しく効果的であると考えられており、市販薬や処方箋で入手可能です。NSAIDsは入手が容易で長期的な鎮痛効果があるため、腰痛の治療薬として医師からもっとも多く処方されています。NSAIDsの価格が安いことも、疼痛管理薬としての人気の一因です。

当レポートでは、世界の慢性腰痛の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の慢性腰痛市場の展望

• 市場規模・予測
• 薬剤クラス別
  • 非ステロイド性抗炎症薬 (NSAIDs)
  • 抗うつ薬
  • 鎮痛剤
  • オピオイド
  • その他
• 投与経路別
  • 経口
  • 局所
  • その他
• エンドユーザー別
  • 病院薬局
  • 小売薬局
  • オンライン薬局
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ
• 企業別市場シェア

第5章 世界の慢性腰痛市場の展望：地域別

• 北米
• 欧州
• アジア太平洋
• 南米
• 中東・アフリカ

第6章 市場マッピング

• 薬剤クラス別
• 投与経路別
• エンドユーザー別
• 地域別

第7章 マクロ環境と産業構造

• 需要供給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長抑制要因（課題、抑制要因）

第9章 規制の枠組みとイノベーション

• 臨床試験
• 特許の情勢
• 規制当局の承認
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析 (参入5社)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Johnson & Johnson Services, Inc.
• Pfizer Inc
• Vertebral Technologies, Inc.
• Merck & Co.
• Medtronic plc
• Boston Scientific Corporation
• Mesoblast Limited
• SpineThera
• Stayble Therapeutics
• Eli Lilly and Company

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 2. Global Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 3. Global Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 4. Global Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 5. Global Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 6. Global Chronic Lower Back Pain Market Share (%), By Region, 2017-2031F
• Figure 7. North America Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 8. North America Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 9. North America Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 10. North America Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 11. North America Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 12. North America Chronic Lower Back Pain Market Share (%), By Country, 2017-2031F
• Figure 13. United States Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 14. United States Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 15. United States Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 16. United States Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 17. United States Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 18. Canada Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 19. Canada Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 20. Canada Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 21. Canada Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 22. Canada Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 23. Mexico Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 24. Mexico Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 25. Mexico Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 26. Mexico Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 27. Mexico Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 28. Europe Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 29. Europe Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 30. Europe Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 31. Europe Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 32. Europe Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 33. Europe Chronic Lower Back Pain Market Share (%), By Country, 2017-2031F
• Figure 34. Germany Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 35. Germany Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 36. Germany Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 37. Germany Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 38. Germany Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 39. France Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 40. France Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 41. France Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 42. France Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 43. France Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 44. Italy Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 45. Italy Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 46. Italy Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 47. Italy Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 48. Italy Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 49. United Kingdom Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 50. United Kingdom Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 51. United Kingdom Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 52. United Kingdom Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 53. United Kingdom Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 54. Russia Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 55. Russia Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 56. Russia Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 57. Russia Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 58. Russia Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 59. Netherlands Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 60. Netherlands Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 61. Netherlands Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 62. Netherlands Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 63. Netherlands Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 64. Spain Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 65. Spain Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 66. Spain Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 67. Spain Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 68. Spain Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 69. Turkey Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 70. Turkey Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 71. Turkey Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 72. Turkey Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 73. Turkey Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 74. Poland Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 75. Poland Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 76. Poland Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 77. Poland Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 78. Poland Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 79. South America Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 80. South America Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 81. South America Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 82. South America Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 83. South America Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 84. South America Chronic Lower Back Pain Market Share (%), By Country, 2017-2031F
• Figure 85. Brazil Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 86. Brazil Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 87. Brazil Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 88. Brazil Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 89. Brazil Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 90. Argentina Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 91. Argentina Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 92. Argentina Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 93. Argentina Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 94. Argentina Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 95. Asia-Pacific Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 96. Asia-Pacific Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 97. Asia-Pacific Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 98. Asia-Pacific Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 99. Asia-Pacific Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 100. Asia-Pacific Chronic Lower Back Pain Market Share (%), By Country, 2017-2031F
• Figure 101. India Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 102. India Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 103. India Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 104. India Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 105. India Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 106. China Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 107. China Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 108. China Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 109. China Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 110. China Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 111. Japan Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 112. Japan Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 113. Japan Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 114. Japan Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 115. Japan Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 116. Australia Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 117. Australia Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 118. Australia Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 119. Australia Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 120. Australia Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 121. Vietnam Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 122. Vietnam Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 123. Vietnam Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 124. Vietnam Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 125. Vietnam Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 126. South Korea Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 127. South Korea Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 128. South Korea Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 129. South Korea Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 130. South Korea Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 131. Indonesia Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 132. Indonesia Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 133. Indonesia Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 134. Indonesia Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 135. Indonesia Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 136. Philippines Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 137. Philippines Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 138. Philippines Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 139. Philippines Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 140. Philippines Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 141. Middle East & Africa Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 142. Middle East & Africa Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 143. Middle East & Africa Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 144. Middle East & Africa Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 145. Middle East & Africa Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 146. Middle East & Africa Chronic Lower Back Pain Market Share (%), By Country, 2017-2031F
• Figure 147. Saudi Arabia Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 148. Saudi Arabia Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 149. Saudi Arabia Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 150. Saudi Arabia Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 151. Saudi Arabia Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 152. UAE Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 153. UAE Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 154. UAE Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 155. UAE Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 156. UAE Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 157. South Africa Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
• Figure 158. South Africa Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
• Figure 159. South Africa Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
• Figure 160. South Africa Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
• Figure 161. South Africa Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
• Figure 162. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 163. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global chronic lower back pain market is projected to witness a CAGR of 6.22% during the forecast period 2024-2031F, growing from USD 8.02 billion in 2023 to USD 12.99 billion in 2031F. The chronic lower back pain market is anticipated to expand under the impact of driving factors such as the growing prevalence of chronic lower back pain, increasing aging population, sedentary lifestyle, rising prevalence of obesity, advancements in pain management solutions, and increased health consciousness. With the growing corporate industry, people are compelled to remain seated for long working hours, which is the main reason behind many such cases.

Another major factor contributing to its rising prevalence is the increasing geriatric population at higher risk of bodily wear and tear. Chronic pain management is mainly done through drug classes like NSAIDs, analgesics, and opioids, either through oral or topical administration. The advancements in the pharmaceutical industry and increased value share of pain management drugs in recent years are evidence for market expansion.

The major challenge for the expansion of the chronic lower back pain market is the side effects associated with pain management drugs. The increasing popularity of alternative pain management techniques like physical therapies (heat or cold packs, massage, hydrotherapy, and exercise) and psychological therapies (cognitive behavioral therapy, relaxation techniques, and meditation) is a restraining factor for the market. Additionally, stringent regulations regarding the use and prescription of painkiller medicines are a challenge for market expansion. Despite these factors, the market is growing at a faster pace.

In May 2023, Abbott announced that it received the U.S. Food and Drug Administration (FDA) approval for its spinal cord stimulation (SCS) devices meant for the treatment of chronic back pain in people not eligible to receive back surgery, called non-surgical back pain. The approval was given based on the result of the study, which demonstrated that Abbott's proprietary BurstDR SCS technology improved pain levels, and the ability to perform daily activities along with emotional well-being in people with chronic back pain.

Growing Prevalence of Lower Back Pain

The chronic lower back pain market is expected to expand due to the increasing prevalence of spinal disorders and back pain cases. The older population is at a higher risk for spinal disorders due to the natural wear and tear of the spine that comes with aging. It is predicted to result in a significant rise in the number of cases of spinal disorders. Additional factors such as obesity, prolonged periods of sitting for working professionals, poor nutrition, lack of physical activity, and a high frequency of accidents resulting in back pain are expected to contribute to a high incidence of lower back pain. Inherited disorders, inflammations, and infections that damage the spine and tissues in the back are contributing to the growth in the prevalence of lower back pain.

World Spine Care estimated that approximately 1 billion people worldwide suffer from spine pain. Every year, about 72% of the global population is expected to experience back pain, while at any given time, around 59% of people are identified with back pain. Lower back pain is the main cause of disability, and neck pain ranks fourth in the global disability list, as estimated by World Spine Care.

Growing Emphasis on Development of Novel Drugs for Pain Management

The development of novel drugs for pain management has been a growing focus in the medical field. Researchers and pharmaceutical companies are increasingly emphasizing the identification and development of innovative drug targets and delivery systems to improve pain relief. It includes targeting specific receptors, ion channels, or signaling pathways involved in pain transmission and modulation. Additionally, nanotechnology-based drug delivery systems have been explored by manufacturers to enhance the efficacy of analgesic drugs and limit their side effects. Despite the presence of several drugs in the market, the quest for more suitable and safer options to manage lower back pain is further expanding the scope of the market.

For instance, in August 2023, Kenvue Inc. announced the showcasing of its two new products at the PAINWeek Conference 2023. The first product is a topical cream called Tylenol Precise Pain-Relieving Cream which will be launched in the United States first. The second product, which was launched earlier, is called Motrin Dual Action with Tylenol. It is a fixed combination pill containing 250 mg of acetaminophen and 125 mg of ibuprofen in each tablet. The pill provides a dose that supports up to 8 hours of pain relief, which is longer than the dosing provided by Tylenol Extra Strength or Motrin1 single ingredient products that can provide up to 6 hours of relief.

Dominance of Non-steroidal Anti-inflammatory Drugs Segment

Non-steroidal anti-inflammatory drugs (NSAIDs) segment is anticipated to dominate the market owing to its widespread efficacy and popularity. NSAIDs are considered equally effective for musculoskeletal pain, including back pain, and are available over the counter or by prescription. These drugs offer easy accessibility and long-term pain relief and, thus are most commonly prescribed by physicians for treating lower back pain. The low cost of NSAIDs is another factor contributing to its popularity as a pain management solution.

For instance, as per an article in the Journal of Orthopedic Research in February 2023, the research findings provided evidence that the combination of muscle relaxants and NSAIDs (paracetamol) was effective in reducing pain and disability in lower back pain at approximately one week.

Oral Route of Administration to be the Dominating Segment

The oral route of administration for chronic lower back pain is anticipated to be the dominating segment owing to the widespread adoption of oral formulations and the advantages associated with it. The oral route of administration offers improved patient compliance, optimum bioavailability, safety, and low-cost access to medications. From the manufacturer's point of view, oral formulations are easy to prepare and dispense and offer a greater margin of safety, thus, it's preferred by them. Most of the pain management drugs available in the market are in the form of oral formulations such as tablets, capsules, and others. Oral opioids, such as morphine, hydromorphone, hydrocodone, and oxycodone, can be used for acute or chronic pain.

North America to Dominate the Market

North America is expected to dominate the chronic lower back pain market, owing to the high prevalence of lower back pain cases in countries like the United States and Canada. The high prevalence of lower back pain can be explained by a sedentary lifestyle, high incidence of obesity, unhealthy food habits, and much more. Along with these factors, the strong pharmaceutical infrastructure and high pharmaceutical expenditures strengthen the lead of North American region.

Furthermore, the presence of major key players in the region and the high cost of medications contribute to high-value share. For instance, as per the Health Policy Institute, Washington, almost 65 million Americans have experienced back pain. Out of these, 16 million adults, which is 8 percent of all adults, suffer from persistent or chronic back pain, and the condition limits certain everyday activities. Additionally, back pain is the sixth most expensive condition in the United States, with healthcare and indirect costs amounting to over USD 12 billion each year.

Future Market Scenario (2024 - 2031F)

The management of chronic lower back pain is undergoing a progressive shift towards more personalized and effective treatments. Researchers are focusing on developing targeted approaches, such as the Biomarkers for Evaluating Spine Treatments (BEST) trial, which aim to use individual biomarkers to guide treatment decisions. Promising new therapies, such as tanezumab, which is a monoclonal antibody capable of inhibiting nerve activity, are showing relief for patients with chronic lower back pain. While in the experimental stage, gene therapy is being explored as a potential method to reverse persistent conditions.

Non-opioid alternatives, such as drugs that inhibit proteins in the bloodstream that heighten the sensitivity of cells in the nervous system to pain, are being developed. Exercise and cognitive behavioral therapy have been proven effective in managing chronic lower back pain. New medications will likely take several years to become available, and their safety and efficacy will need to be thoroughly tested before they can be widely adopted.

Key Players Landscape and Outlook

The key players in the chronic lower back pain market include Pfizer Inc., Vertebral Technologies, Inc., Merck & Co., Medtronic plc, Boston Scientific Corporation, and many more players. These players have diverse product portfolios, and a focus on R&D initiatives. Other prominent players include Novartis AG, and Atherna Biosciences. The market is expected to be driven by the increasing aging population with age-related disorders, rising healthcare awareness, and increasing disposable income of consumers. The market is expected to be hampered by the side effects of treatments and the availability of counterfeit drugs.

In September 2023, Boston Scientific offered USD 850 million to acquire back pain ablation tech maker Relievant Medsystems, which is a Minnesota-based provider of an ablation system to treat chronic lower back pain.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Chronic Lower Back Pain Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Drug Class
  • 4.2.1. Non-steroidal Anti-inflammatory Drugs
  • 4.2.2. Antidepressants
  • 4.2.3. Analgesics
  • 4.2.4. Opioids
  • 4.2.5. Others
• 4.3. By Route of Administration
  • 4.3.1. Oral
  • 4.3.2. Topical
  • 4.3.3. Others
• 4.4. By End-user
  • 4.4.1. Hospital Pharmacies
  • 4.4.2. Retail Pharmacies
  • 4.4.3. Online Pharmacies
• 4.5. By Region
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia-Pacific
  • 4.5.4. South America
  • 4.5.5. Middle East and Africa
• 4.6. By Company Market Share (%), 2023

5. Global Chronic Lower Back Pain Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. By Value
    • 5.1.1.2. By Volume
  • 5.1.2. By Drug Class
    • 5.1.2.1. Non-steroidal Anti-inflammatory Drugs
    • 5.1.2.2. Antidepressants
    • 5.1.2.3. Analgesics
    • 5.1.2.4. Opioids
    • 5.1.2.5. Others
  • 5.1.3. By Route of Administration
    • 5.1.3.1. Oral
    • 5.1.3.2. Topical
    • 5.1.3.3. Others
  • 5.1.4. By End-user
    • 5.1.4.1. Hospital Pharmacies
    • 5.1.4.2. Retail Pharmacies
    • 5.1.4.3. Online Pharmacies
  • 5.1.5. United States*
    • 5.1.5.1. Market Size & Forecast
    • 5.1.5.1.1. By Value
    • 5.1.5.1.2. By Volume
    • 5.1.5.2. By Drug Class
    • 5.1.5.2.1. Non-steroidal Anti-inflammatory Drugs
    • 5.1.5.2.2. Antidepressants
    • 5.1.5.2.3. Analgesics
    • 5.1.5.2.4. Opioids
    • 5.1.5.2.5. Others
    • 5.1.5.3. By Route of Administration
    • 5.1.5.3.1. Oral
    • 5.1.5.3.2. Topical
    • 5.1.5.3.3. Others
    • 5.1.5.4. By End-user
    • 5.1.5.4.1. Hospital Pharmacies
    • 5.1.5.4.2. Retail Pharmacies
    • 5.1.5.4.3. Online Pharmacies
  • 5.1.6. Canada
  • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3. Asia-Pacific
  • 5.3.1. India
  • 5.3.2. China
  • 5.3.3. Japan
  • 5.3.4. Australia
  • 5.3.5. Vietnam
  • 5.3.6. South Korea
  • 5.3.7. Indonesia
  • 5.3.8. Philippines
• 5.4. South America
  • 5.4.1. Brazil
  • 5.4.2. Argentina
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Drug Class
• 6.2. By Route of Administration
• 6.3. By End-user
• 6.4. By Region

7. Macro Environment and Industry Structure

• 7.1. Demand Supply Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.4.7. Supplier Power
  • 7.4.8. Buyer Power
  • 7.4.9. Substitution Threat
  • 7.4.10. Threat from New Entrant
  • 7.4.11. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

• 9.1. Clinical Trials
• 9.2. Patent Landscape
• 9.3. Regulatory Approvals
• 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. Johnson & Johnson Services, Inc.
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus & Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. Pfizer Inc
• 13.3. Vertebral Technologies, Inc.
• 13.4. Merck & Co.
• 13.5. Medtronic plc
• 13.6. Boston Scientific Corporation
• 13.7. Mesoblast Limited
• 13.8. SpineThera
• 13.9. Stayble Therapeutics
• 13.10. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer